Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-3801 vs Gonal-F in Anovulatory Infertility
NCT01820728Phase 3Completed
- Sponsor
- Dong-A ST
- Start
- Jan 2007
- Primary completion
- Oct 2012
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of follitropin alfa biosimilar DA-3801 in female infertility and anovulation (2 arms), sponsored by Dong-A ST. Primary endpoint: The ovulation rate after 3 cycles of the injection at 5 weeks. Started Jan 2007; status: completed.
02
Drugs
follitropin alfa biosimilar DA-3801
03
Conditions
female infertilityanovulation
Beyond the preview
Go deeper on NCT01820728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01820728.